INDIVIDUAL ARTICLE: Fixed Combination Calcipotriene/Betamethasone (Cal/BDP) Cream: Evaluating the Role of Polyaphron Dispersion (PAD) Technology in Psoriasis Treatment
Journal of Drugs in Dermatology · 2023
DOI: 10.36849/jdd.sf381621s5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Drugs in Dermatology, 2023. Verfasst von Rasika Reddy und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Dermatologic Agents, Psoriasis. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Most patients with plaque psoriasis exhibit mild-to-moderate disease and topical therapies remain the mainstay treatment option for these patients. The use of topical steroids in combination with vitamin D analogs can produce synergistic effects and minimize adverse effects. However, due to the incompatible pH ranges of topical steroids and vitamin D analogs, combination formulations can be difficult to manufacture. Until recently, only anhydrous formulations of these 2 agents were developed as foam, gel/suspension, and ointment. However, anhydrous vehicles can often result in greasy or oily skin, thus limiting treatment adherence. Recently, Polyaphron Dispersion (PAD) technology presents a new, more cosmetically appealing vehicle that allows for both topical steroids and vitamin D analogs to coexist in an aqueous environment, such as a cream formulation. The calcipotriene/betamethasone dipropionate (CAL/BDP) cream enhances drug delivery by reducing the greasy and oily side effects of anhydrous formulations. Phase 3 clinical trials have demonstrated CAL/BDP cream’s superior efficacy in treating psoriasis over gel/suspension, and the clinical trials have also shown significantly improved patient satisfaction with the cream formulation. .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Reddy, R., Khan, S., Kircik, L., & Armstrong, A. W. (2023). INDIVIDUAL ARTICLE: Fixed Combination Calcipotriene/Betamethasone (Cal/BDP) Cream: Evaluating the Role of Polyaphron Dispersion (PAD) Technology in Psoriasis Treatment. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.sf381621s5
Vancouver
Reddy R, Khan S, Kircik L, Armstrong AW. INDIVIDUAL ARTICLE: Fixed Combination Calcipotriene/Betamethasone (Cal/BDP) Cream: Evaluating the Role of Polyaphron Dispersion (PAD) Technology in Psoriasis Treatment. Journal of Drugs in Dermatology. 2023. doi:10.36849/jdd.sf381621s5
BibTeX
@article{Reddy2023,
author = {Reddy, Rasika and Khan, Samiya and Kircik, Leon and Armstrong, April W},
title = {INDIVIDUAL ARTICLE: Fixed Combination Calcipotriene/Betamethasone (Cal/BDP) Cream: Evaluating the Role of Polyaphron Dispersion (PAD) Technology in Psoriasis Treatment},
journal = {Journal of Drugs in Dermatology},
year = {2023},
doi = {10.36849/jdd.sf381621s5}
}
EUVIMED